Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2841 - Does the minimal axillary approach lead to lose of prognostic factors in breast cancer?

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy;  Pathology/Molecular Biology

Tumour Site

Breast Cancer

Presenters

Rogerio de Araujo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

R.A. de Araujo1, C.P. Nascimento2, C.L.P. Da Cunha2, E.D.C. Marinho2, E.R.T. Mosca2, F.A.C. Da Luz2, P.F.R. Delfino2, R.M. Antonioli2, T.R. Mendes2, M.J.B. Silva3

Author affiliations

  • 1 Oncologia Clínica, COT - Centro Oncológico do Triângulo, 38408-150 - Uberlandia/BR
  • 2 Hospital Do Câncer Em Uberlândia, Universidade Federal de Uberlândia, Uberlândia/BR
  • 3 Instituto De Ciências Biomédicas, Universidade Federal de Uberlândia, Uberlândia/BR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2841

Background

There are several factors for metastasis in breast cancer, such as tumor size (T) and lymph node involvement (N). In this study was investigated the association of T and N with metastasis in breast cancer patients treated in the Oncology Sector of a public Hospital of Minas Gerais.

Methods

Observational and retrospective study. A total of 1671 medical records of women with breast cancer treated in the period of 1981-2013 were analyzed, of which 797 were excluded for lack of pathologic data or by being diagnosed in advanced stage. Fisher’s exact test or χ2 were performed.

Results

As expected, the positivity of lymph node metastasis increased with tumor size: of the Tis patients, 5.55% were N + (3.7% N1, 1.85 N2); of T1, 25.29% were N + (21.01% N1, 4.28% N2); of T2, 51.45% were N + (37.21% N1; 9.88% N2; 4.36% N3); of T3, 77.05% were N + (55.74% N1; 18.03% N2; 3.28% N3); and of T4, 80% were N + (48.57% N1; 17.14% N2; 14.29% N3). When analyzed by T, decreased odds of metastasis in Tis (OR = 0.3435; p = 0.0197) and T1 (OR = 0.3805; p < 0.0001) were observed, while increased odds in T2 (OR = 1.469; p = 0.0364), T3 (OR = 2.114; p = 0.0081) and T4 (OR = 4.222; p < 0.0001). When analyzed by N, decreased odds of metastasis in N0 (OR = 0.1587; p < 0.0001) was observed and increased odds in N1 (OR = 2.56; p < 0.0001), N2 (OR = 3.703; p < 0.0001) and N3 (OR = 4.328; p = 0.0002). Overall, N+ had an increased odd of metastasis when compared with N- (OR = 6.321; p < 0.0001) patients. Increased odds only in T1N + (OR = 9.49; p < 0.0001) and T2N + (OR = 3.557; p < 0.0001) was observed when compared with their N- counterparts. Moreover, a borderline increase in the odds (OR = 3.667; p = 0.0533) was observed in T1N2 compared with in T1N1, but not in T2 (p = 0.9190) nor T3 (p = 0.4639) patients.

Conclusions

Lymph node involvement (N) is a greater risk factor for metastasis than tumor size (T). Adjuvant therapy is based on T, N and molecular subtype. In the minimal axillary approach by sentinel lymph node (SL) the pathologic analysis of this unique sample, and maybe including two other lymph nodes, have a great prognostic weight, mainly in early stage. These data corroborate the lack of necessity in dividing, as formerly, between the 12 or more dissected lymph nodes in a clinically negative axilla.

Clinical trial identification

Legal entity responsible for the study

Grupo Luta Pela Vida.

Funding

Grupo Luta Pela Vida.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.